What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2021-03-26 compared with 2020-03-25 · 677 added, 402 removed, 126 unchanged (90% of the section changed)

MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Company’s common stock is traded on the OTCQB under the symbol “LIXT”.

As of March 1, 2020, the Company had

73 stockholders of record holding 67,045,814 shares of the Company’s common stock outstanding, including 6,745,785 shares

of common stock held by an indeterminate number of beneficial owners of securities whose shares are held in the names of various

brokerage firms and clearing agencies.

November 25, 2020, the Company’s common stock and Warrants began to trade on The Nasdaq Capital Market under the symbols

“LIXT”

and “LIXTW”, respectively.

Prior to November 30, 2020, the Company’s common stock traded

on the OTCQB.

The stock market in general has experienced extreme stock price fluctuations in the past few years.

In some cases,

these fluctuations have been unrelated to the operating performance of the affected companies.

Many companies have experienced

dramatic volatility in the market prices of their common stock.

The Company believes that a number of factors, both within and

outside its control, could cause the price of the Company’s common stock to fluctuate, perhaps substantially.

following table sets forth the range of reported closing prices of the Company’s common stock during the periods presented.

Such quotations reflect prices between dealers in securities and do not include any retail mark-up, markdown or commissions, and

may not necessarily represent actual transactions.

share and per share amounts and information presented herein have been retroactively adjusted for all periods presented to reflect

the 1-for-6 reverse stock split effected November 18, 2020.

Year Ended December 31, 2019

First Quarter

Second Quarter

Third Quarter

Fourth Quarter

Year Ended December 31, 2020

First Quarter

Second Quarter

Third Quarter

Fourth Quarter

of March 12, 2021, the Company had 61 stockholders of record holding 13,538,259 shares of the Company’s common stock outstanding,

including 7,096,582 shares of common stock held by an indeterminate number of beneficial owners of securities whose shares are

held in the names of various depository accounts, brokerage firms and clearing agencies.

Company’s dividend policy is determined by its Board of Directors and will depend upon a number of factors, including the

4 unchanged sentences

in the foreseeable future.

Authorized For Issuance Under Equity Incentive Plans

forth in the table below is information regarding awards made through compensation plans or arrangements through December 31,

2020, the most recently completed fiscal year.

Plan Category

securities to be

exercise of outstanding

Weighted average price of outstanding options, warrants and rights

Number of securities remaining available for future issuance compensation plans (excluding securities reflected in column 2)

Equity Compensation Plans Approved by Security Holders

Equity Compensation Plans Not Approved by Security Holders

2,133,333 (1)

The Company’s 2007 Stock Option Plan terminated on June 19, 2017.

The 2,133,333 shares that remain available are pursuant

to the Company’s 2020 Stock Incentive Plan, which was adopted on July 14, 2020 (see “ITEM 11.

EXECUTIVE COMPENSATION”).

SELECTED FINANCIAL DATA

6 unchanged sentences

have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases.

Company’s activities are subject to significant risks and uncertainties, including the need for additional capital, as described

The Company has not yet commenced any revenue-generating operations, does not have positive cash flows from operations,

and is dependent on periodic infusions of equity capital to fund its operating requirements.

Company’s common stock is traded on the OTCQB operated by the OTC Markets under the symbol “LIXT”.

Company’s consolidated financial statements have been presented on the basis that it is a going concern, which contemplates

the realization of assets and satisfaction of liabilities in the normal course of business.

The Company has not generated any

revenues from operations to date and does not expect to do so in the foreseeable future.

Furthermore, the Company has experienced

recurring operating losses and negative operating cash flows since inception and has financed its working capital requirements

during this period primarily through the recurring sale of its equity securities and the exercise of outstanding common stock

options and purchase warrants.

Company’s activities are subject to significant risks and uncertainties, including the need for additional capital.

Company has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, and is dependent

on periodic infusions of equity capital to fund its operating requirements.

November 18, 2020, the Company effected a 1-for-6 reverse split of its outstanding shares of common stock.

No fractional shares

were issued in connection with the reverse split, with any fractional shares resulting from the reverse split were rounded up

to the nearest whole share.

share and per share amounts and information presented herein have been retroactively adjusted to reflect the reverse stock split

for all periods presented.

of Common Stock

March 2, 2021, the Company completed the sale of 1,133,102 shares of common stock at a price of $3.70 per share in a registered

direct equity offering, generating gross proceeds of $4,192,477.

The total cash costs of this offering were approximately $502,447,

resulting in net proceeds of approximately $3,690,030.

Pursuant to the placement agents’

agreement, the Company granted

to the placement agents warrants to purchase up to 113,310 shares of common stock commencing on March 2, 2021 and expiring on

March 2, 2026, at an exercise price of $3.70 per share.

December 31, 2020, the Company had cash of $5,069,266 available to fund its operations.

Because the Company is currently engaged

in Phase 2 clinical trials, it is expected that it will take a significant amount of time and resources to develop any product

or intellectual property capable of generating sustainable revenues.

Accordingly, the Company’s business is unlikely to

generate any sustainable operating revenues in the next several years and may never do so.

Even if the Company is able to generate

revenues through licensing its technologies or through product sales, there can be no assurance that the Company will be able

to achieve positive earnings and operating cash flows.

Company’s consolidated financial statements have been presented on the basis that it will continue as a going concern, which

contemplates the realization of assets and satisfaction of liabilities in the normal course of business.

The Company has no recurring

source of revenue and has experienced negative operating cash flows since inception.

The Company has financed its working capital

requirements primarily through the recurring sale of its equity securities.

a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern

within one year of the date that the consolidated financial statements are being issued.

In addition, the Company’s independent

registered public accounting firm, in their report on the Company’s consolidated financial statements for the year ended

December 31, 2019, has also expressed substantial doubt about the Company’s ability to continue as a going concern.

Company’s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund

its research and development activities and to ultimately achieve sustainable operating revenues and profits.

within one year of the date that the accompanying consolidated financial statements have been issued.

The Company’s independent

registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended December

31, 2020, has also expressed substantial doubt about the Company’s ability to continue as a going concern.

The Company’s

consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

the Company is currently engaged in Phase 2 clinical trials, it is expected that it will take a significant amount of time to

develop any product or intellectual property capable of generating sustainable revenues.

Accordingly, the Company’s business

is unlikely to generate any sustainable operating revenues in the next several years and may never do so.

In addition, to the

extent that the Company is able to generate revenues through licensing its technologies or through product sales, there can be

no assurance that the Company will be able to achieve positive earnings and operating cash flows.

December 31, 2019, the Company had cash and cash equivalents of $2,598,864 available to fund its operations.

Because the Company

is currently engaged in Phase 2 clinical trials, it is expected that it will take a significant amount of time to develop any

product or intellectual property capable of generating sustainable revenues.

Accordingly, the Company’s business is unlikely

to generate any sustainable operating revenues in the next several years and may never do so.

In addition, to the extent that

the Company is able to generate revenues through licensing its technologies or through product sales, there can be no assurance

that the Company will be able to achieve positive earnings and operating cash flows.

Company’s longer-term objective is to secure one or more strategic partnerships or licensing agreements with pharmaceutical

companies with major programs in cancer.

The Company expects that it will need to begin to raise additional capital no later than

the fourth quarter of 2020.

amount and timing of future cash requirements will depend on the pace and design of the Company’s clinical trial program.

As market conditions present uncertainty as to the Company’s ability to secure additional funds, there can be no assurances

that the Company will be able to secure additional financing on acceptable terms, or at all, as and when necessary to continue

to conduct operations.

The impact of the coronavirus on capital markets may affect the availability, amount and type of financing

available to the Company in the future.

cash resources are insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to scale

back or discontinue its clinical trial program and its technology and product development efforts, or obtain funds, if available

(although there can be no certainty), through strategic alliances that may require the Company to relinquish rights to certain

of its compounds, or to discontinue its operations entirely.

consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Accounting Pronouncements

Adopted Accounting Standards

June 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”)

2018-07, Compensation –

Stock Compensation (Topic 718):

Improvements to Nonemployee Share-Based Payment Accounting (“ASU

2018-07”).

ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and

services from nonemployees.

ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively

provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of

a contract accounted for under Revenue from Contracts with Customers (Topic 606).

ASU 2018-07 was effective for fiscal years beginning

after December 15, 2018, including interim periods within those fiscal years.

The Company adopted the provisions of ASU 2018-07

effective January 1, 2019 (see “Stock-Based Compensation”

The adoption of ASU 2018-07 did not have any impact

on the Company’s financial statement presentation or disclosures subsequent to its adoption.

Issued Accounting Standards

December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740):

Simplifying the Accounting for Income Taxes (“ASU

2019-12”).

ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions and enhances and simplifies

various aspects of the income tax accounting guidance in ASC 740.

ASU 2019-12 is effective for fiscal years, and interim periods

within those fiscal years, beginning after December 15, 2020.

The adoption of ASU 2018-07 is not expected to have any impact on

the Company’s financial statement presentation or disclosures subsequent to its adoption.

December 2019, the Financial Accounting Standards board (the “FASB”) issued Accounting Standards Update (“ASU”)

2019-12, Income Taxes (Topic 740):

Simplifying the Accounting for Income Taxes (“ASU 2019-12”).

ASU 2019-12 simplifies

the accounting for income taxes by removing certain exceptions and enhances and simplifies various aspects of the income tax accounting

guidance in ASC 740.

ASU 2019-12 will be effective January 1, 2021.

The adoption of ASU 2019-12 is not expected to have any impact

on the Company’s consolidated financial statement presentation or disclosures subsequent to its adoption.

August 2020, the FASB issued ASU 2020-06, Debt —

Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives

and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):

Accounting for Convertible Instruments and Contracts

in an Entity’s Own Equity (“ASU 2020-06).

ASU 2020-06 simplifies the accounting for convertible debt by eliminating

the beneficial conversion and cash conversion accounting models.

Upon adoption of ASU 2020-06, convertible debt proceeds, unless

issued with a substantial premium or an embedded conversion feature that is not clearly and closely related to the host contract,

will no longer be allocated between debt and equity components.

This modification will reduce the issue discount and result in

less non-cash interest expense in financial statements.

ASU 2020-06 also updates the earnings per share calculation and requires

entities to assume share settlement when the convertible debt can be settled in cash or shares.

ASU 2020-06 will be effective

January 1, 2024, and a cumulative-effect adjustment to the opening balance of retained earnings is required upon adoption.

adoption is permitted, but no earlier than January 1, 2021, including interim periods within that year.

The adoption of ASU 2020-06

is not expected to have any impact on the Company’s consolidated financial statement presentation or disclosures subsequent

to its adoption, with any effect being largely dependent on the composition and terms of outstanding financial instruments at

the time of adoption.

does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have

1 unchanged sentence

Concentration

Company periodically contracts with vendors and consultants to provide services related to the Company’s research and development

Agreements for these services can be for a specific time period (typically one year) or for a specific project or

The only such contract that represented 10% or more of general and administrative costs or research and development costs

for the years ended December 31, 2019 and 2018 is described below.

as of July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the

Spanish Sarcoma Group (“GEIS”) to carry out a clinical trial entitled “Randomized phase I/II trial of LB-100

plus doxorubicin vs.

doxorubicin alone in first line of advanced soft tissue sarcoma”.

The Company estimates that this clinical

trial will be completed and results will be published by June 2023.

Costs incurred pursuant to the agreement with GEIS are included

in research and development costs in the Company’s consolidated statements of operations.

During the year ended December

31, 2019, the Company incurred costs of $87,471 pursuant to this agreement, reflecting 10.7% of total research and development

costs for such period.

Company periodically contracts with vendors and consultants to provide services related to the Company’s operations.

incurred for these services can be for a specific time period (typically one year) or for a specific project or task.

expenses incurred that represented 10% or more of general and administrative costs or research and development costs for the years

ended December 31, 2020 and 2019 are described as follows.

and administrative costs for the years ended December 31, 2020 and 2019 include charges from a legal firm for general licensing

and patent prosecution costs relating to the Company’s intellectual properties representing 27.3% and 44.5%, respectively,

of total general and administrative costs.

General and administrative costs for the years ended December 31, 2020 and 2019 also

include charges for the amortized value of stock options granted to directors and officers representing 23.7% and 18.8%, respectively,

of total general and administrative costs.

and development costs for the year ended December 31, 2020 include charges from a consultant, and the value associated with extending

stock options previously granted to that consultant, representing 65.6% of total research and development costs, and charges from

a vendor representing 13.7% of total research and development costs.

Research and development costs for the year ended December

31, 2019 include charges for the value associated with fully-vested stock options granted to a consultant representing 52.9% of

total research and development costs, and charges from a consultant and from a vendor representing 12.2% and 10.7%, respectively,

of total research and development costs.

Accounting Policies and Estimates

preparation of the Company’s consolidated financial statements in conformity with generally accepted accounting principles

in the United States (“GAAP”) requires management to make estimates and assumptions that affect the amounts reported

in the consolidated financial statements and the notes to the consolidated financial statements.

Some of those judgments can be

subjective and complex, and therefore, actual results could differ materially from those estimates under different assumptions

or conditions.

in the United States (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts

of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.

Some of those judgments can be subjective and complex, and therefore, actual results could differ materially from those estimates

under different assumptions or conditions.

Management bases its estimates on historical experience and on various assumptions

that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results

of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent

from other sources.

Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently

available information, changes in facts and circumstances, historical experience and reasonable assumptions.

After such evaluations,

if deemed appropriate, those estimates are adjusted accordingly.

Actual results could differ from those estimates.

estimates include those related to assumptions used in accruals for potential liabilities, valuing equity instruments issued for

services, and the realization of deferred tax assets.

following critical accounting policies affect the more significant judgements and estimates used in the preparation of the Company’s

1 unchanged sentence

and Development

and development costs consist primarily of fees paid to consultants and outside service providers, and other expenses relating

to the acquisition, design, development and testing of the Company’s compounds and product candidates.

and development costs consist primarily of fees paid to consultants and contractors, and other expenses relating to the acquisition,

design, development and clinical trials with respect to the Company’s compounds and product candidates.

Research and development

costs also include the costs to produce the compounds used in research and clinical trials.

and development costs are charged to operations ratably over the life of the underlying contracts, unless the achievement of milestones,

the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate.

incurred with respect to mandatory scheduled payments under research agreements without milestone provisions are recognized ratably

over the appropriate period, as specified in the agreement, and are recorded as liabilities in the Company’s consolidated

balance sheet, with a corresponding charge to research and development costs in the Company’s consolidated statement of

incurred with respect to mandatory scheduled payments under research agreements with milestone provisions are recognized as charges

to research and development costs in the Company’s consolidated statement of operations based on the achievement of such

milestones, as specified in the agreement.

Obligations incurred with respect to mandatory scheduled payments under research agreements

without milestone provisions are recognized ratably over the appropriate period, as specified in the agreement, and are recorded

as liabilities in the Company’s consolidated balance sheet, with a corresponding charge to research and development costs

in the Company’s consolidated statement of operations.

made pursuant to research and development contracts are initially recorded as advances on research and development contract services

in the Company’s consolidated balance sheet and then charged to research and development costs in the Company’s consolidated

statement of operations as those contract services are performed.

Expenses incurred under research and development contracts in

excess of amounts advanced are recorded as research and development contract liabilities in the Company’s consolidated balance

sheet, with a corresponding charge to research and development costs in the Company’s consolidated statement of operations.

in the Company’s consolidated balance sheet and are then charged to research and development costs in the Company’s

consolidated statement of operations as those contract services are performed.

Expenses incurred under research and development

contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s consolidated

balance sheet, with a corresponding charge to research and development costs in the Company’s consolidated statement of

The Company reviews the status of its research and development contracts on a quarterly basis.

3 unchanged sentences

legal fees are charged to operations as incurred.

Patent and licensing related legal and filing costs were $742,918 and $842,325

for the years ended December 31, 2019 and 2018, respectively.

Patent and licensing related legal and filing costs are included

in general and administrative costs in the Company’s consolidated statements of operations.

Company periodically issues common stock and stock options to officers, directors, Scientific Advisory Committee members and consultants

for services rendered.

Options vest and expire according to terms established at the issuance date of each grant.

Stock grants,

which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting

December 31, 2018, the Company accounted for stock-based payments to officers and directors by measuring the cost of services

received in exchange for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation

expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards.

accounted for stock-based payments to Scientific Advisory Committee members and consultants by determining the value of the stock

compensation based upon the measurement date at either (a) the date at which a performance commitment was reached or (b) at the

date at which the necessary performance to earn the equity instruments was complete.

accordance with the Company’s adoption of Accounting Standards Update 2018-07, Compensation –

Stock Compensation (Topic

Improvements to Nonemployee Share-Based Payment Accounting, effective January 1, 2019, stock options granted to members

of the Company’s Scientific Advisory Committee and to outside consultants are now accounted for consistent with the accounting

for stock-based payments to officers and directors, as described above, by measuring the cost of services received in exchange

for equity awards utilizing the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line

basis in the Company’s financial statements over the vesting period of the awards.

Patent and licensing related legal and filing costs are included in general

and administrative costs in the Company’s consolidated statements of operations.

Company periodically issues common stock and stock options to officers, directors, employees, Scientific Advisory Committee members,

contractors and consultants for services rendered.

Options vest and expire according to terms established at the issuance date

of each grant.

Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations

ratably over the vesting period.

Company accounts for stock-based payments to officers, directors, employees, Scientific Advisory Committee members contractors

and consultants by measuring the cost of services received in exchange for equity awards utilizing the grant date fair value of

the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements

over the vesting period of the awards.

fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model,

and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the

stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common

Estimated volatility is based on the historical volatility of the Company’s common stock, calculated utilizing a

one-year look-back period, as the Company believes that such measurement period provides a more accurate and meaningful volatility

factor given the changes in the Company’s research and development program and capital requirements over the past several

and is affected by several variables, the most significant of which are the expected life of the stock option, the exercise price

of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of

the common stock.

Unless sufficient historical exercise data is available, the expected life of the stock option is calculated

as the mid-point between the vesting period and the contractual term (the “simplified method”).

Estimated volatility

is based on the historical volatility of the Company’s common stock, calculated utilizing a look-back period approximately

equal to the contractual life of the stock option being granted.

The risk-free interest rate is based on the U.S.

Treasury yield curve in effect at the time of grant.

The fair market value

of the common stock is determined by reference to the quoted market price of the Company’s common stock on the grant date.

Treasury yield

curve in effect at the time of grant.

The fair market value of the common stock is determined by reference to the quoted market

price of the Company’s common stock on the grant date.

Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development

2 unchanged sentences

to satisfy stock option exercises.

Company has two classes of drugs under development for the treatment of cancer, consisting of protein phosphatase inhibitors (PTase-i),

designated by the Company as the LB-100 series of compounds, and histone deacetylase inhibitors (HDACi), designated by the Company

as the LB-200 series of compounds.

Compounds of both types also have potential use in the prevention and treatment of neurodegenerative

The LB-100 series consists of novel structures, which have the potential to be first in their class and may be useful

in the treatment of not only several types of cancer, but also vascular and metabolic diseases.

The LB-200 series contains compounds

which have the potential to be the most effective in its class and may be useful for the treatment of chronic hereditary diseases,

such as Gaucher’s disease, in addition to cancer and neurodegenerative diseases.

Company’s immediate goals are to demonstrate significant therapeutic benefit of LB-100, the Company’s lead anti-cancer

clinical compound, against one or more specific human cancers in Phase 2 clinical trials.

The Company has several attractive targets

for new therapies incorporating LB-100.

The potentiation of cancer immunotherapy by adding LB-100 to regimens of PD-1 blockers,

as reported by Ho et al (2018), and the unexpected findings of Muschen et al (2018) that a metabolic imbalance involving over

activity of the enzyme PP2A in B cell cancers, which is the target of LB-100, may provide a selective advantage in the therapy

of B cell cancers.

These findings have also led the Company to reexamine the most attractive cancer targets for demonstrating

the clinical effectiveness of LB-100 and to enter into discussions with cancer centers that focus on the inhibition of PP2A as

an important cancer target.

has not yet advanced to the clinical stage and would require additional capital to fund further development.

Accordingly, because

of the Company’s focus on the clinical development of LB-100 and analogs for cancer therapy as described below in more detail,

the Company has decided not to actively pursue the pre-clinical development of its LB-200 series of compounds at this time.

this time, the Company intends to only maintain its composition of matter patents for LB-200.

of Business Activities and Plans

Company is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases

and then designs novel compounds to attack those targets.

The Company’s product pipeline is primarily focused on inhibitors

of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and

encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes

have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases.

Company has developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series.

The Company believes

that the mechanism by which compounds of the LB-100 series affect cancer cell growth is different from cancer agents currently

approved for clinical use.

Lead compounds from each series have activity against a broad spectrum of common and rarer human cancers

in cell culture systems.

In addition, compounds from both series have anti-cancer activity in animal models of glioblastoma multiforme,

neuroblastoma, and medulloblastoma, all cancers of neural tissue.

Lead compounds of the LB-100 series also have activity against

melanoma, breast cancer and sarcoma in animal models and enhance the effectiveness of commonly used anti-cancer drugs in these

model systems.

The enhancement of anti-cancer activity of these anti-cancer drugs occurs at doses of LB-100 that do not significantly

increase toxicity in animals.

It is therefore hoped that, when combined with standard anti-cancer regimens against many tumor

types, the Company’s compounds will improve therapeutic benefit without enhancing toxicity in humans.

LB-100 series consists of novel structures which have the potential to be first in their class and may be useful in the treatment

of not only several types of cancer but also vascular and metabolic diseases.

The LB-200 series contains compounds which have

the potential to be the most effective in its class and may be useful for the treatment of chronic hereditary diseases, such as

Gaucher’s disease, in addition to cancer and neurodegenerative diseases.

Company has demonstrated that lead compounds of both the LB-100 series and the LB-200 are active against a broad spectrum of human

cancers in cell culture and against several types of human cancers in animal models.

The research on these compounds was initiated

in 2006 under a Cooperative Research and Development Agreement, or CRADA, with the National Institute of Neurologic Disorders

and Stroke, or NINDS, of the National Institutes of Health, or NIH, dated March 22, 2006 that was subsequently extended through

a series of amendments until it terminated on April 1, 2013.

As discussed below, the Company’s primary focus is on the clinical

development of LB-100.

LB-200 series consists of histone deacetylase inhibitors (HDACi).

Many pharmaceutical companies are also developing drugs of this

type, and at least two companies have HDACi approved for clinical use, in both cases for the treatment of a type of lymphoma.

Despite this significant competition, the Company has demonstrated that its HDACi have broad activity against many cancer types,

have neuroprotective activity, and have anti-fungal activity.

In addition, these compounds have low toxicity.

LB-200 has not yet

advanced to the clinical stage and would require additional capital to fund further development.

Accordingly, because of the Company’s

focus on the clinical development of LB-100 and analogs for cancer therapy as described below in more detail, the Company have

decided not to actively pursue the pre-clinical development of our LB-200 series of compounds at this time.

At this time, the

Company intend to only maintain composition of matter patents for LB-200.

Collaborations

with leading academic research centers in the United States, Europe and Asia have established the breadth of activity of LB-100

in pre-clinical models of several major cancers.

There is considerable scientific interest in LB-100 because it exerts its activity

by a novel mechanism and is the first of its type to be evaluated so broadly in multiple animal models of cancer and now in human

LB-100 is one of a series of serine/threonine phosphatase (s/t ptase) inhibitors designed by the Company.

The s/t ptases

are ubiquitous enzymes that regulate many cell signaling networks important to cell growth, division and death.

The s/t ptases

have long been appreciated as potentially important targets for anti-cancer drugs.

However, because of the multi- functionality

of these enzymes, it had been widely held that pharmacologic inhibitors of s/t ptases would be too toxic to allow their development

as anti-cancer treatments, but the Company has shown that this is not the case.

LB-100 was well tolerated at doses associated

with objective regression (significant tumor shrinkage) and/or the arresting of tumor progression in patients with progressive

studies showed that LB-100 itself inhibits a spectrum of human cancers and that combined with standard cytotoxic drugs and/or

radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing toxicity.

at very low doses in animal models of cancer, LB-100 markedly increased the effectiveness of a PD-1 blocker, one of the widely

used new immunotherapy drugs.

This finding raises the possibility that LB-100 may further expand the value of the expanding field

of cancer immunotherapy.

Company completed a Phase 1 clinical trial of LB-100 to evaluate its safety that showed it is associated with antitumor activity

in humans at doses that are readily tolerable.

Responses included objective regression (tumor shrinkage) lasting for 11 months

of a pancreatic cancer and cessation of growth (stabilization of disease) for 4 months or more of 9 other progressive solid tumors

out of 20 patients who had measurable disease.

As Phase 1 clinical trials are fundamentally designed to determine safety of a

new compound in humans, the Company was encouraged by these results.

The next step is to demonstrate in Phase 2 clinical trials

the efficacy of LB-100 in one or more specific tumor types, against which the compound has well documented activity in pre-clinical

a compound moves through the FDA-approval process, it becomes an increasingly valuable property, but at a cost of additional investment

5 unchanged sentences

stages as certain milestones are reached.

The Company’s longer-term objective is to secure one or more strategic partnerships

or licensing agreements with pharmaceutical companies with major programs in cancer.

of the Novel Coronavirus (COVID-19) on the Company’s Business Operations

global outbreak of the novel coronavirus (COVID-19) has led to severe disruptions in general economic activities worldwide, as

businesses and governments have taken broad actions to mitigate this public health crisis.

In light of the uncertain and continually

evolving situation relating to the spread of COVID-19, this pandemic could pose a risk to the Company.

The extent to which the

coronavirus may impact the Company’s business operations will depend on future developments, which are highly uncertain

and cannot be predicted at this time.

The Company intends to continue to monitor the situation and may adjust its current business

plans as more information and guidance become available.

coronavirus pandemic presents a challenge to medical facilities worldwide.

As the Company’s clinical trials are conducted

on an outpatient basis, it is not currently possible to predict the full impact of this developing health crisis on such clinical

trials, which could include delays in and increased costs of such clinical trials.

Current indications from the clinical research

organizations conducting the clinical trials for the Company are that such clinical trials are being delayed or extended for several

months as a result of the coronavirus pandemic.

is also significant uncertainty as to the effect that the coronavirus may have on the amount and type of financing available to

the Company in the future.

of Operations

9 unchanged sentences

Interest income

Interest expense

$ (3,264,882 )

8 unchanged sentences

For the year ended December 31, 2020, general and administrative costs were $2,042,764, which consisted

of the fair value of vested stock options issued to directors and a consultant of $314,631, patent and licensing legal fees and

of the fair value of vested stock options issued to officers and consultants of $580,634, patent and licensing legal fees and

costs of $553,173, other consulting and professional fees of $403,983, insurance expense of $142,575, officer’s salary and

related costs of $268,457, licensing fees of $25,001, stock transfer fees of $11,801, listing fees of $12,000, filing fees of

and other operating costs of $24,571.

$10,616, travel of $718, and other operating costs of $33,806.

the year ended December 31, 2019, general and administrative costs were $1,669,160, which consisted of the fair value of vested

stock options issued to directors and consultants of $785,612 (including the cost of extending certain stock options previously

granted to a consultant of $711,738), patent and licensing legal fees and costs of $842,325, other consulting and professional

fees of $300,649, insurance expense of $52,060, officer’s salary and related costs of $67,656, stock transfer fees of $12,822,

listing fees of $12,000, filing fees of $7,490, and other operating costs of $16,734.

and administrative costs decreased by $428,188 or 20.4% in 2019 as compared to 2018, primarily as a result of decreases in the

fair value of stock options issued to directors and consultants of $470,981, and patent and licensing legal fees and costs of

$99,407, offset by increases in licensing fees of $80,669, and other consulting and professional fees of $49,885.

stock options issued to officers and consultants of $314,631, patent and licensing legal fees and costs of $742,918, other consulting

and professional fees of $350,534, insurance expense of $55,935, officer’s salary and related costs of $67,684, licensing

fees of $80,669, stock transfer fees of $10,202, listing fees of $12,000, filing fees of $10,016, travel of $4,703, and other

operating costs of $19,868.

and administrative costs increased by $373,604 or 22.4% in 2020 as compared to 2019, primarily as a result of an increase in the

fair value of vested stock options issued to officers and consultants of $266,003, an increase in officer’s salary and related

costs of $200,773, an increase in insurance expense of $86,640, offset by a decrease in patent and licensing legal fees and costs

and Development Costs .

For the year ended December 31, 2019, research and development costs were $820,906, which consisted

of the fair value of vested stock options issued to a consultant of $434,024, and contractor costs, primarily in connection with

the Company’s pre-clinical research focused on the development of additional novel anti-cancer compounds to add to its clinical

pipeline, including $87,471 to with respect to GEIS, and $100,000 to BioPharma Works.

the year ended December 31, 2018, research and development costs were $40,703, which consisted entirely of contractor costs, primarily

in connection with the Company’s pre-clinical research focused on the development of additional novel anti-cancer compounds

to add to its clinical pipeline, including $10,000 to BioPharma Works, .and is stated net of a credit of $25,000 for a reversal

of an obligation to the NCI in connection with Amendment No.

3 to the M-CRADA, which updated collaboration plans between the NCI

and the Company.

and development costs increased by $780,203 in 2019 as compared to 2018, as a result of an increase in the fair value of vested

stock options issued to a consultant of $434,024, and contractor costs, primarily in connection with the Company’s pre-clinical

For the year December 31, 2020, research and development costs were $1,223,676, which consisted of

the fair value of vested stock options issued to consultants of $670,715, and contractor costs, primarily in connection with the

Company’s pre-clinical research focused on the development of additional novel anti-cancer compounds to add to its clinical

pipeline, including $43,411 to GEIS, $41,142 to Moffitt, $31,388 to Theradex, $131,650 to BioPharmaWorks, $167,120 to a contract

research and development firm for the synthesis work to develop a new supply of LB-100 for the GEIS clinical trial, and $138,250

to various other contractors.

the year ended December 31, 2019, research and development costs were $820,906, which consisted of the fair value of vested stock

options issued to consultants of $434,024, and contractor costs, primarily in connection with the Company’s pre-clinical

research focused on the development of additional novel anti-cancer compounds to add to its clinical pipeline, including $87,471

with respect to GEIS, and $90,000 to BioPharma Works.

to GEIS, $45,093 to Moffitt, $64,624 to Theradex, $100,000 to BioPharmaWorks and $89,694 to various other contractors.

and development costs increased by $402,770 in 2020 as compared to 2019, primarily as a result of an increase in the fair value

of vested stock options issued to consultants of $236,691 and an increase in contractor costs, primarily in connection with the

Company’s pre-clinical research focused on the development of additional novel anti-cancer compounds to add to its clinical

For the year ended December 31, 2020, the Company had interest income of $5,232, as compared to interest income of

$4,923 for the year ended December 31, 2018, as a result of the Company investing the majority of its cash resources in short-term

federally insured certificates of deposit beginning in 2019.

$49,723 for the year ended December 31, 2019, as a result of a reduction in the Company’s cash resources previously invested

in short-term federally insured certificates of deposit.

For the year ended December 31, 2020, the Company had interest expense of $3,674 related to the financing of its

directors and officers liability insurance premium.

The Company had no interest expense during the year ended December 31, 2019.

For the year ended December 31, 2020, the Company incurred a net loss of $3,264,882, as compared to a net loss of $2,440,343

2 unchanged sentences

December 31, 2020

Company’s consolidated financial statements have been presented on the basis that it is a going concern, which contemplates

the realization of assets and satisfaction of liabilities in the normal course of business.

The Company has not generated any

revenues from operations to date and does not expect to do so in the foreseeable future.

Furthermore, the Company has experienced

recurring operating losses and negative operating cash flows since inception and has financed its working capital requirements

during this period primarily through the recurring sale of its equity securities and the exercise of outstanding common stock

options and purchase warrants.

As a result, management has concluded that there is substantial doubt about the Company’s

ability to continue as a going concern within one year of the date that the consolidated financial statements are being issued.

In addition, the Company’s independent registered public accounting firm, in their report on the Company’s consolidated

financial statements for the year ended December 31, 2019, has also expressed substantial doubt about the Company’s ability

to continue as a going concern (see “Going Concern”

December 31, 2020, the Company had working capital of $5,011,951, as compared to working capital of $2,434,135 at December 31,

2018, reflecting a decrease in working capital of $1,689,395 for the year ended December 31, 2019.

The decrease in working capital

during the year ended December 31, 2019 was the result of working capital being utilized to fund the Company’s research

and development activities and ongoing operating expenses, including maintaining and developing the Company’s patent portfolio.

December 31, 2019, the Company had cash and cash equivalents of $2,598,864 available to fund its operations.

Because the Company

is currently engaged in Phase 2 clinical trials, it is expected that it will take a significant amount of time to develop any

product or intellectual property capable of generating sustainable revenues.

Accordingly, the Company’s business is unlikely

to generate any sustainable operating revenues in the next several years and may never do so.

In addition, to the extent that

the Company is able to generate revenues through licensing its technologies or through product sales, there can be no assurance

that the Company will be able to achieve positive earnings and operating cash flows.

Company’s longer-term objective is to secure one or more strategic partnerships or licensing agreements with pharmaceutical

companies with major programs in cancer.

The Company expects that it will need to begin to raise additional capital no later than

the fourth quarter of 2020.

amount and timing of future cash requirements will depend on the pace and design of the Company’s clinical trial program.

As market conditions present uncertainty as to the Company’s ability to secure additional funds, there can be no assurances

that the Company will be able to secure additional financing on acceptable terms, or at all, as and when necessary to continue

to conduct operations.

The impact of the coronavirus on capital markets may affect the availability, amount and type of financing

available to the Company in the future.

2019, reflecting an increase in working capital of $2,577,816 for the year ended December 31, 2020.

The increase in working capital

during the year ended December 31, 2020 was the result of the net cash proceeds of $4,591,349 from the Company’s November

2020 public offering, which are being utilized to fund the Company’s research and development activities and ongoing operating

expenses, including the Company’s clinical trial program and maintaining and developing the patent portfolio.

31, 2020, the Company had cash and cash equivalents of $5,069,266 available to fund its operations.

Company’s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund

its research and development activities and to ultimately achieve sustainable operating revenues and profitability.

and timing of future cash requirements depends on the pace and design of the Company’s clinical trial program, which, in

turn, depends on the availability of operating capital to fund such activities.

November 30, 2020, the Company listed on The Nasdaq Capital Market in conjunction with the completion of its public offering of

units of common stock and warrants that generated net cash proceeds of $4,591,349.

Subsequently, on January 18, 2021, the Company

entered into a clinical trial agreement to carry out a Phase 1b clinical trial of LB-100, combined with a standard regimen for

untreated, extensive stage-disease small cell lung cancer.

This new clinical trial is being conducted through City of Hope, and

is estimated to cost from $2,500,000 to $2,900,000 and take approximately 18 to 24 months to conduct from its expected commencement

during the quarter ending June 30, 2021.

Combined with the Company’s existing clinical trial commitments, this new clinical

trial commitment represents an additional demand on the Company’s working capital resources.

Although the Company completed

a sale of common stock under a registered direct equity offering on March 2, 2021 that generated net proceeds of approximately

$3,690,000, the Company estimates that it will need to raise additional capital to fund its operations, including its various

clinical trial commitments, by mid-2022.

In addition, the Company’s operating plan may change as a result of many factors

which are currently unknown to the Company, including possible additional clinical trials, and the Company may need additional

funds sooner than currently planned.

market conditions present uncertainty as to the Company’s ability to secure additional funds, there can be no assurances

that the Company will be able to secure additional financing on acceptable terms, as and when necessary to continue to conduct

There is also significant uncertainty as to the effect that the coronavirus may have on the Company’s clinical

trial schedule and the amount and type of financing available to the Company in the future.

cash resources are insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to scale

back or discontinue its clinical trial program and its technology and product development efforts, or obtain funds, if available

(although there can be no certainty), through strategic alliances that may require the Company to relinquish rights to certain

of its compounds, or to discontinue its operations entirely.

back or discontinue its clinical trial program, as well as its licensing and patent prosecution efforts and its technology and

product development efforts, or obtain funds, if available, through strategic alliances or joint ventures that could require the

Company to relinquish rights to and/or control of LB-100, or to discontinue operations entirely.

For the year ended December 31, 2020, operating activities utilized cash of $2,131,414, as compared to utilizing

2 unchanged sentences

For the years ended December 31, 2020 and 2019, the Company had no investing activities.

For the year ended December 31, 2019, the Company had no financing activities.

For the year ended December 31,

2018, financing activities consisted of net proceeds from the sale of 9,000,000 common stock units on November 30, 2018, in the

amount of $4,475,298, and $3,000 received from the exercise of stock options to acquire 20,000 shares of the Company’s common

stock at an exercise price of $0.15 per share.

For the year December 31, 2020, financing activities consisted of the gross proceeds from the sales of units and

warrants in the Company’s public offering of $5,701,800, offset by the payment of offering costs of $1,099,984.

had no financing activities for the year ended December 31, 2019.

Trial Agreements

August 20, 2018, the Company and the Moffitt Cancer Center and Research Institute Hospital Inc., Tampa, Florida (“Moffitt”)

entered into a Clinical Trial Research Agreement (the “Clinical Trial Research Agreement”) effective for a term of

five years, unless terminated earlier by the Company pursuant to 30 days written notice.

Pursuant to the Clinical Trial Research

Agreement, Moffitt agreed to conduct and manage a Phase 1b/2 clinical trial to evaluate the therapeutic benefit of the Company’s

lead anti-cancer clinical compound LB-100 to be administered intravenously in patients with low or intermediate-1 risk myelodysplastic

syndrome (MDS).

In November 2018, the Company received approval from the FDA for its Investigational New Drug (IND) Application

to conduct a Phase 1b/2 clinical trial to evaluate the therapeutic benefit of LB-100 in patients with low and intermediate-1 risk

MDS who have failed or are intolerant of standard treatment.

This clinical trial began in April 2019 and the first patient was

entered into the clinical trial in July 2019.

During the years ended December 31, 2019 and 2018, the Company paid Moffitt $45,093

and $0, respectively, pursuant to this agreement.

As of December 31, 2019, total costs of $45,093 have been incurred pursuant

to this agreement.

as of July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with the

Spanish Sarcoma Group (Grupo Espanol de Investigacion en Sarcomas or “GEIS”), Madrid, Spain, to carry out a clinical

trial entitled “Randomized phase I/II trial of LB-100 plus doxorubicin vs.

doxorubicin alone in first line of advanced soft

tissue sarcoma”.

The purpose of this clinical trial is to obtain information about the efficacy and safety of the Company’s

lead anti-cancer clinical compound LB-100 combined with doxorubicin in soft tissue sarcomas.

Doxorubicin is the global standard

for initial treatment of advanced soft tissue sarcomas (ASTA).

Doxorubicin alone has been the mainstay of first line treatment

of ASTS for over 40 years, with little therapeutic gain from adding cytotoxic compounds to or substituting other cytotoxic compounds

for doxorubicin.

In animal models, LB-100 consistently enhances the antitumor activity of doxorubicin without apparent increases

GEIS has a network of referral centers in Span and across Europe that have an impressive track record of efficiently

conducting innovative studies in ASTS.

The Company has agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct

of this clinical trial, as well as to provide funding for the clinical trial.

The goal is to enter the first patient into this

clinical trial during the quarter ending June 30, 2020, with approximately 170 patients to be subsequently enrolled over a period

of two years.

The Company estimates that this clinical trial will be completed and results will be published by June 30, 2023.

The original start date for patient entry was delayed due to longer than expected processing

of formal approval of importation of LB-100 into the European Union.

This approval was originally expected to be received in the

quarter ended September 30, 2019, but was delayed and is now expected to be received during the quarter ending June 30, 2020.

During the year ended December 31, 2019, the Company incurred costs of $87,471 pursuant to this agreement.

As of December

31, 2019, total costs of $87,471 have been incurred pursuant to this agreement.

Company’s aggregate commitments pursuant to these clinical trial agreements, less amounts previously incurred to date under

these agreements, totaled approximately $5,000,000 as of December 31, 2019, which are expected to be incurred over the next five

years through 2024.

Effective August 20, 2018, the Company entered into a Clinical Trial Research Agreement with the Moffitt Cancer Center and

Research Institute Hospital Inc., Tampa, Florida (“Moffitt”), effective for a term of five years, unless terminated

earlier by the Company pursuant to 30 days written notice.

Pursuant to the Clinical Trial Research Agreement, Moffitt agreed to

conduct and manage a Phase 1b/2 clinical trial to evaluate the therapeutic benefit of the Company’s lead anti-cancer clinical

compound LB-100 to be administered intravenously in patients with low or intermediate-1 risk myelodysplastic syndrome (MDS).

November 2018, the Company received approval from the U.S.

Food and Drug Administration for its Investigational New Drug Application

(“IND”) to conduct a Phase 1b/2 clinical trial to evaluate the therapeutic benefit of LB-100 in patients with low

and intermediate-1 risk MDS who have failed or are intolerant of standard treatment.

Patients with MDS, although usually older,

are generally well except for severe anemia requiring frequent blood transfusions.

This Phase 1b/2 clinical trial utilizes LB-100

as a single agent in the treatment of patients with low and intermediate-1 risk MDS, including patients with del(5q) myelodysplastic

syndrome (del5qMDS) failing first line therapy.

The bone marrow cells of patients with del5qMDS are deficient in PP2A by virtue

of an acquired mutation and are especially vulnerable to further inhibition of PP2A by LB-100.

The clinical trial began at a single

site in April 2019 and the first patient was entered into the clinical trial in July 2019.

A total enrollment of 41 patients is

An interim analysis will be done after the first 21 patients are entered.

If there are 3 or more responders but fewer

than 7, an additional 20 patients will be entered.

If at any point there are 7 or more responders, this will be sufficient evidence

to support continued development of LB-100 for the treatment of low and intermediate-1 risk MDS.

Recruitment has been slow and

the Covid-19 pandemic has further reduced recruitment of patients into the protocol.

At the current rate of accrual, the trial

would be completed over a period of four years from its initiation, with the final analysis and reporting expected by July 2023.

However, with additional funds, the Company’s objective would be to add two additional MDS centers to the Phase 2 portion

of the study to accelerate patient accrual, with the goal of an earlier reporting date.

the years ended December 31, 2020 and 2019, the Company paid Moffitt $41,142 and $45,093, respectively, pursuant to this agreement.

As of December 31, 2020, total costs of $102,944 have been incurred pursuant to this agreement.

Effective July 31, 2019, the Company entered into a Collaboration Agreement for an Investigator-Initiated Clinical Trial with

the Spanish Sarcoma Group (Grupo Español de Investigación en Sarcomas or “GEIS”), Madrid, Spain, to

carry out a study entitled “Randomized phase I/II trial of LB-100 plus doxorubicin vs.

doxorubicin alone in first line of

advanced soft tissue sarcoma”.

The purpose of this clinical trial is to obtain information about the efficacy and safety

of LB-100 combined with doxorubicin in soft tissue sarcomas.

Doxorubicin is the global standard for initial treatment of advanced

soft tissue sarcomas (“ASTS”).

Doxorubicin alone has been the mainstay of first line treatment of ASTS for over 40

years, with little therapeutic gain from adding cytotoxic compounds to or substituting other cytotoxic compounds for doxorubicin.

In animal models, LB-100 consistently enhances the anti-tumor activity of doxorubicin without apparent increases in toxicity.

has a network of referral centers in Spain and across Europe that have an impressive track record of efficiently conducting innovative

studies in ASTS.

The Company agreed to provide GEIS with a supply of LB-100 to be utilized in the conduct of this clinical trial,

as well as to provide funding for the clinical trial.

The goal was to enter the first patient during the quarter ending December

31, 2020, with approximately 150 patients to be enrolled over two years.

Advanced sarcoma is a very aggressive disease.

of the study assumes a median progression free survival (PFS, no evidence of disease progression or death from any cause) of 4.5

months in the doxorubicin arm and an alternative median PFS of 7.5 months in the doxorubicin plus LB-100 arm to demonstrate a

statistically significant decrease in relative risk of progression or death by adding LB-100.

There is a planned interim analysis

of the primary endpoint when about half of the 102 events required for final analysis is reached.

Company had previously expected that this clinical trial would commence during the quarter ended June 30, 2020.

However, during

July 2020, the Spanish regulatory authority advised the Company that although it had approved the scientific and ethical basis

of the protocol, it required that the Company manufacture new inventory of LB-100 under current Spanish pharmaceutical manufacturing

These regulations were adopted subsequent to the production of the Company’s existing LB-100 inventory.

is in the process of obtaining approval from the European Union regulatory authorities for new inventory of LB-100.

the clinical trial is now estimated to begin during the quarter ending September 30, 2021 and to be completed by the quarter ending

September 30, 2024.

The interim analysis is expected in June 2023 and could indicate either inferiority or superiority of LB-100

plus doxorubicin as compared to doxorubicin alone.

A positive study would have the potential to change the standard therapy for

this disease after four decades of failure to improve the marginal benefit of doxorubicin alone.

Company’s agreement with GEIS provides for various payments based on achieving specific milestones over the term of the

On February 18, 2020, the Company advanced $43,411 to GEIS towards a second milestone payment obligation of $87,471,

which was expected to become due and payable during the quarter ended June 30, 2020 based on the anticipated achievement of the

second milestone, and which was therefore recorded as an advance on the Company’s balance sheet at March 31, 2020.

as a result of the substantial delay in commencing the clinical trial as described above, the achievement of the second milestone

had been delayed until mid-2021 and the Company therefore determined to charge such advance to research and development costs

in the Company’s statement of operations at June 30, 2020.

Subsequently, on March 9, 2021, the Company paid an additional

$23,802 to GEIS for current work being done under this agreement.

during the years ended December 31, 2020 and 2019, the Company incurred costs of $43,411 and $87,471, respectively, pursuant to

this agreement.

As of December 31, 2020, total costs of $130,882 have been incurred pursuant to this agreement.

Company’s aggregate commitments pursuant to the aforementioned clinical trial agreements, less amounts previously paid to

date under these agreements, totaled approximately $5,230,000 as of December 31, 2020, consisting of approximately $4,614,000

relating to the GEIS clinical trial and approximately $616,000 relating to the Moffit clinical trial, which are expected to be

incurred over the next five years through December 31, 2025.

order to manufacture a new inventory supply of LB-100 for the GEIS clinical trial, the Company has engaged a number of vendors

to carry out the multiple tasks needed to make and gain approval of a new clinical product for investigational study in Spain.

These tasks include the synthesis under good manufacturing practices (GMP) of the active pharmacologic ingredient (API), with

documentation of each of the steps involved by an independent auditor.

The API is then transferred to a vendor that prepares the

clinical drug product (DP), also under GMP conditions documented by an independent auditor.

The DP is then sent to a vendor to

test for purity and sterility, provide appropriate labels, store the drug, and distribute the drug to the clinical centers for

use in the clinical trials.

A formal application documenting all steps taken to prepare the DP for clinical use must be submitted

to the appropriate regulatory authorities for review and approval before being used in a clinical trial.

Company estimates that this program to provide new inventory of the DP for the Spanish sarcoma study, and potentially for subsequent

multiple trials within the European Union, will cost from $600,000 and $700,000.

The Company’s remaining aggregate commitments

under this program, less amounts previously paid to date, totaled approximately $300,000 as of December 31, 2020, which are expected

to be incurred through June 30, 2021.

Trial Agreement Entered into Subsequent to December 31, 2020

Effective January 18, 2021, the Company executed a Clinical Research Support Agreement with City of Hope National

Medical Center, an NCI-designated comprehensive cancer center, and City of Hope Medical Foundation (collectively, “City

of Hope”), to carry out a Phase 1b clinical trial of LB-100, the Company’s first-in-class protein phosphatase inhibitor,

combined with a standard regimen for untreated, extensive stage-disease small cell lung cancer (ED-SCLC).

LB-100 will be given

in combination with carboplatin, etoposide and atezolizumab, an FDA-approved but marginally effective regimen, to previously untreated

ED-SCLC patients.

The dose of LB-100 will be escalated with the standard fixed doses of the 3-drug regimen to reach a recommended

Phase 2 dose (RP2D).

Patient entry will be expanded so that a total of 12 patients will be evaluable at the RP2D to confirm the

safety of the LB-100 combination and to look for potential therapeutic activity as assessed by objective response rate, duration

of overall response, progression-free-survival and overall survival.

Company estimates that from 24 to 30 patients will be needed to complete this clinical trial, at an estimated cost of $2,500,000

to $2,900,000, respectively.

If a significant number of patients fail during the dose-escalation process, an increase of up to

12 patients would likely be necessary, at an estimated additional cost of $800,000.

clinical trial is planned to commence during the quarter ending June 30, 2021, with patient accrual expected to take approximately

18 to 24 months to conduct.

If LB-100 does potentiate the benefit of the standard regimen, some evidence could be noted at 12

months into the clinical trial, but an assessment of potential increased activity is likely to require at least 24 months.

Trial Monitoring Agreements

September 12, 2018, the Company finalized a work order agreement with Theradex Systems, Inc.

(Theradex”), an international

(“Theradex”), an international

contract research organization (“CRO”), to monitor the Phase 1b/2 clinical trial being managed and conducted by Moffitt.

The clinical trial is expected to be completed over a period of two years, with final analysis and reporting expected within three

Costs under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided

approximately 94% to Theradex for services and approximately 6% for payments for pass-through costs.

The costs of the Phase 1b/2

clinical trial being paid to or through Theradex are being recorded and charged to operations based on the periodic documentation

provided by the CRO.

During the years ended December 31, 2019 and 2018, the Company incurred costs of $51,586 and $11,906, respectively,

pursuant to this work order.

The clinical trial began in April 2019 and the first patient was entered into the clinical trial in July 2019.

At the current

rate of accrual, the trial would be completed over a period of four years from its initiation, with the final analysis and reporting

expected by July 2023.

under this work order agreement are estimated to be approximately $954,000, with such payments expected to be divided approximately

94% to Theradex for services and approximately 6% for payments for pass-through costs.

The costs of the Phase 1b/2 clinical trial

being paid to or through Theradex are being recorded and charged to operations based on the periodic documentation provided by

During the years ended December 31, 2020 and 2019, the Company incurred costs of $18,663 and $51,586, respectively, pursuant

to this work order.

As of December 31, 2020, total costs of $75,788 have been incurred pursuant to this work order agreement.

Company expects to enter into a separate work order agreement with Theradex to monitor the GEIS clinical trial as described above.

Company’s aggregate commitments pursuant to this clinical trial monitoring agreement, less amounts previously paid to date

under this agreement, totaled approximately $874,000 as of December 31, 2020, which are expected to be incurred over the next

five years through June 30, 2025.

February 5, 2021, the Company signed a new work order agreement with Theradex to monitor the City of Hope investigator-initiated

clinical trial in small cell lung cancer in accordance with FDA requirements for oversight by the sponsoring party.

estimates that it will incur approximately $335,000 of costs under this work order agreement through September 30, 2023.

and License Agreements

March 22, 2018, the Company entered into a Patent Assignment and Exploitation Agreement (the “Agreement”) with INSERM

TRANSFERT SA, acting as delegatee of the French National Institute of Health and Medical Research (“INSERM”), for

the assignment to the Company of INSERM’S interest in United States Patent No.

9,833,450 entitled “Oxabicyloheptanes

and Oxabicycloheptenes for the Treatment of Depressive and Stress Disorders”, which was filed with the United States Patent

and Trademark Office in the name of INSERM and the Company as co-owners on February 19, 2015 and granted on May 12, 2017, and

related patent applications and filings.

INSERM is a French public institution dedicated to research in the field of health and

medicine that had previously entered into a Material Transfer Agreement (“MTA”) with the Company to allow INSERM to

conduct research on the Company’s proprietary compound LB-100 and/or its analogs for the treatment of depressive or stress

disorders in humans.

Pursuant to the Agreement, the Company has agreed to make certain milestone payments to INSERM aggregating

up to $1,750,000 upon achievement of development milestones and up to $6,500,000 upon achievement of commercial milestones.

Company also agreed to pay INSERM certain commercial royalties on net sales of products attributed to the Agreement.

The Company’s

current plan is to complete the validation process to evaluate LB-100 for the treatment of depressive or stress disorders in humans

within three years;

however, the exploitation of this patent for the treatment of depressive and stress disorders in humans will

require substantial additional capital and/or a joint venture or other type of business arrangement with a pharmaceutical company

with substantially greater capital and business resources than those available to the Company.

As there can be no assurances that

the Company will be able to obtain the capital or business resources necessary to focus on the exploitation of this patent, it

is uncertain when the Company may reach any of the development or commercialization milestones under the Agreement, if at all.

March 22, 2018, the Company entered into a Patent Assignment and Exploitation Agreement with INSERM TRANSFERT SA, acting as delegatee

of the French National Institute of Health and Medical Research, for the assignment to the Company of INSERM’S interest

in United States Patent No.

9,833,450 entitled “Oxabicyloheptanes and Oxabicycloheptenes for the Treatment of Depressive

and Stress Disorders”, which was filed with the United States Patent and Trademark Office in the name of INSERM and the

Company as co-owners on February 19, 2015 and granted on May 12, 2017, and related patent applications and filings.

a French public institution dedicated to research in the field of health and medicine that had previously entered into a Material

Transfer Agreement (“MTA”) with the Company to allow INSERM to conduct research on the Company’s proprietary

compound LB-100 and/or its analogs for the treatment of depressive or stress disorders in humans.

Pursuant to the Agreement, the

Company has agreed to make certain milestone payments to INSERM aggregating up to $1,750,000 upon achievement of development milestones

and up to $6,500,000 upon achievement of commercial milestones.

The Company also agreed to pay INSERM certain commercial royalties

on net sales of products attributed to the Agreement.

The Company’s current plan is to complete the validation process to

evaluate LB-100 for the treatment of depressive or stress disorders in humans within three years;

however, the exploitation of

this patent for the treatment of depressive and stress disorders in humans will require substantial additional capital and/or

a joint venture or other type of business arrangement with a pharmaceutical company with substantially greater capital and business

resources than those available to the Company.

As there can be no assurances that the Company will be able to obtain the capital

or business resources necessary to focus on the exploitation of this patent, it is uncertain as to when, if at all, the Company

may reach any of the development or commercialization milestones under the Agreement.

As of December 31, 2020 and 2019, no amounts

were due under this agreement.

April 2, 2018, the Company entered into a consulting agreement for a term of two years with Liberi Life Sciences Consultancy BV,

located in The Netherlands, for consulting and advisory services with respect to sales and licensing, as well as the procurement

of investors in China, Japan and South Korea (the “Consulting Agreement”).

The Consulting Agreement provided for the

payment of a fixed, one-time retainer of EURO 15,000 (US $18,348), which was paid on April 5, 2018, and 2.5% of the net payments

received by the Company from sales of products or licensing activities arising directly and exclusively from leads generated by

the advisor during the term of the Consulting Agreement, and any investors introduced to the Company by the advisor that results

in an investment in the Company during the term of the Consulting Agreement.

The Company recorded the payment of the retainer

as a prepaid expense in the Company’s consolidated balance sheet, and is amortizing the retainer payment over the two-year

life of the Consulting Agreement, as a result of which the Company recorded a charge to operations of $9,174 and $6,881 during

the years ended December 31, 2019 and 2018, respectively.

At December 31, 2019, the unamortized balance of the retainer payment

was $2,294, all of which was classified as a current asset in the Company’s consolidated balance sheet at such date.

December 31, 2018, the unamortized balance of the retainer payment was $11,468, of which $9,175 was classified as a current asset

and $2,293 was classified as a non-current asset in the Company’s consolidated balance sheet at such date.

August 20, 2018 (the “Effective Date”), the Company and Moffitt entered into an Exclusive License Agreement (the “License

Agreement”).

Pursuant to the License Agreement, Moffitt granted the Company an exclusive license under certain patents owned

by Moffitt (the “Licensed Patents”) relating to the treatment of MDS and a non-exclusive license under inventions,

concepts, processes, information, data, know-how, research results, clinical data, and the like (other than the Licensed Patents)

necessary or useful for the practice of any claim under the Licensed Patents or the use, development, manufacture or sale of any

product for the treatment of MDS which would otherwise infringe a valid claim under the Licensed Patents.

The Company is obligated

to pay Moffitt a non-refundable license issue fee of $25,000 after the first patient is entered into a Phase 1b/2 clinical trial

to be managed and conducted by Moffitt.

The clinical trial began in April 2019 and the first patient was entered into the clinical

trial in July 2019.

The clinical trial is expected to be completed over a period of two years, with final analysis and reporting

expected within three years.

The Company is also obligated to pay Moffitt an annual license maintenance fee of $25,000 commencing

on the first anniversary of the Effective Date and every anniversary thereafter until the Company commences payment of minimum

royalty payments.

The Company has also agreed to pay non-refundable milestone payments to Moffitt, which cannot be credited against

earned royalties payable by the Company, based on reaching various clinical and commercial milestones aggregating $1,897,000,

subject to reduction by 40% under certain circumstances relating to the status of Valid Claims, as such term is defined in the

License Agreement.

During the years ended December 31, 2019 and 2018, the Company recorded charges to operations of $80,669 and

$0, respectively, in connection with its obligations under the License Agreement.

of investors in China, Japan and South Korea.

The Consulting Agreement provided for the payment of a fixed, one-time retainer

of EURO 15,000 (US $18,348), which was paid on April 5, 2018, and 2.5% of the net payments received by the Company from sales

of products or licensing activities arising directly and exclusively from leads generated by the advisor during the term of the

Consulting Agreement, and any investors introduced to the Company by the advisor that results in an investment in the Company

during the term of the Consulting Agreement.

The Company recorded the payment of the retainer as a prepaid expense in the Company’s

consolidated balance sheet and amortized the retainer payment over the two-year life of the Consulting Agreement, as a result

of which the Company recorded charges to operations of $2,294 and $9,174 during the years ended December 31, 2020 and 2019, respectively.

As of December 31, 2020, the prepaid consulting fee had been fully amortized.

At December 31, 2019, the unamortized balance of

the retainer payment was $9,174, all of which was classified as a current asset in the Company’s consolidated balance sheet

at such date.

On March 1, 2020, the Consulting Agreement was extended to April 2, 2021 without any additional consideration.

August 20, 2018, the Company entered into an Exclusive License Agreement with Moffitt.

Pursuant to the License Agreement, Moffitt

granted the Company an exclusive license under certain patents owned by Moffitt relating to the treatment of MDS and a non-exclusive

license under inventions, concepts, processes, information, data, know-how, research results, clinical data, and the like (other

than the Licensed Patents) necessary or useful for the practice of any claim under the Licensed Patents or the use, development,

manufacture or sale of any product for the treatment of MDS which would otherwise infringe a valid claim under the Licensed Patents.

The Company was obligated to pay Moffitt a non-refundable license issue fee of $25,000 after the first patient is entered into

a Phase 1b/2 clinical trial to be managed and conducted by Moffitt.

The clinical trial began at a single site in April 2019 and

the first patient was entered into the clinical trial in July 2019.

The Company is also obligated to pay Moffitt an annual license

maintenance fee of $25,000 commencing on the first anniversary of the Effective Date and every anniversary thereafter until the

Company commences payment of minimum royalty payments.

The Company has also agreed to pay non-refundable milestone payments to

Moffitt, which cannot be credited against earned royalties payable by the Company, based on reaching various clinical and commercial

milestones aggregating $1,897,000, subject to reduction by 40% under certain circumstances relating to the status of Valid Claims,

as such term is defined in the License Agreement.

During the years ended December 31, 2020 and 2019, the Company recorded charges

to operations of $25,001 and $80,669, respectively, in connection with its obligations under the License Agreement.

As of December

31, 2020, no milestones had yet been attained.

Company will be obligated to pay Moffitt earned royalties of 4% on worldwide cumulative net sales of royalty-bearing products,

7 unchanged sentences

date on which the last valid claim of the Licensed Patents expires, lapses, or is declared to be invalid in all countries.

John Kovach .

On July 15, 2020, the Company entered into an employment agreement with Dr.

John Kovach pursuant to which Dr.

Kovach is to continue to act as the Company’s President, Chief Executive Officer and Chief Scientific Officer.

His responsibilities

shall be for the oversight of the Company’s entire operations and strategic planning, and shall be the primary contact between

the Company’s executive team and the Board of Directors, to whom he shall report.

Kovach shall supervise all scientific

endeavors, providing guidance to the Chief Medical Officer.

He shall be the principal spokesperson for the Company.

will receive an annual salary of $250,000, payable monthly.

The effective date of the agreement was October 1, 2020 and shall

remain in effect until the earlier of (i) one year from the effective date, automatically renewable for additional one-year periods

unless terminated by either party upon 60 days written notice prior to the end of the applicable one-year period, (ii) his death,

or (iii) termination for cause.

During the year ended December 31, 2020, the Company incurred charges for salary in the amount

of $62,500 with respect to this agreement, which amount is included in general and administrative costs in the Company’s

consolidated statements of operations.

On July 15, 2020, as amended on August 12, 2020, the Company entered into an employment agreement with Eric Forman,

pursuant to which Mr.

Forman will act as the Company’s Chief Administrative Officer reporting directly to the Company’s

Chief Executive Officer.

Forman’s primary function shall be to oversee the Company’s internal operations, including

IT, licensing, legal, personnel, marketing, and corporate governance.

Forman will receive an annual salary of $120,000, payable

Forman was also granted stock options to acquire 350,000 shares of the Company’s common stock.

The effective

date of the agreement was October 1, 2020 and shall remain in effect until the earlier of (i) one year from the effective date,

automatically renewable for additional one-year periods unless terminated by either party upon 60 days written notice prior to

the end of the applicable one-year period, (ii) his death, or (iii) termination for cause.

During the year ended December 31,

2020, the Company incurred charges for salary in the amount of $30,000 with respect to this agreement, which amount is included

in general and administrative costs in the Company’s consolidated statements of operations.

James Miser .

On August 1, 2020, the Company entered into an employment agreement with Dr.

James Miser, M.D., pursuant to which

Miser was appointed as the Company’s Chief Medical Officer.

Under the employment agreement, Dr.

Miser will play a leadership

role in planning, implementation and oversight of clinical trials.

Miser will be responsible for assisting and developing

strategic clinical goals and the implementation and safety monitoring of investigational studies.

Miser will be the primary

medical monitor for all clinical investigational studies and for the oversight of third party CRO monitors.

Miser will work

closely with the Company’s Chief Executive Officer on the development of specific goals needed to ensure the timely implementation

of appropriate clinical studies needed for successful registration of therapeutic products and new drug development.

will be required to devote at least 50% of his business time to the Company’s activities.

Miser will receive an annual

salary of $150,000.

Miser was also granted stock options to acquire 500,000 shares of the Company’s common stock.

effective date of the agreement was August 1, 2020.

The agreement shall remain in effect until the earlier of (i) one year from

the effective date, automatically renewable for additional one-year periods unless terminated by either party upon 60 days written

notice prior to the end of the applicable one-year period, (ii) his death, or (iii) termination for cause.

During the year ended

December 31, 2020, the Company incurred charges for salary in the amount of $62,500 with respect to this agreement, which amount

is included in general and administrative costs in the Company’s consolidated statements of operations.

On August 12, 2020, the Company entered into an employment agreement with Robert N.

Weingarten pursuant to

Weingarten was appointed as the Company’s Vice-President and Chief Financial Officer.

Weingarten will receive

an annual salary of $120,000.

Weingarten was also granted stock options to acquire 350,000 shares of the Company’s common

The effective date of the agreement was August 12, 2020.

The agreement shall remain in effect until the earlier of (i)

one year from the effective date, automatically renewable for additional one-year periods unless terminated by either party upon

60 days written notice prior to the end of the applicable one-year period, (ii) his death, or (iii) termination for cause.

the year ended December 31, 2020, the Company incurred charges for salary in the amount of $46,451 with respect to this agreement,

which amount is included in general and administrative costs in the Company’s consolidated statements of operations.

Significant Agreements and Contracts

October 18, 2013, the Company entered into a Materials Cooperative Research and Development Agreement (M-CRADA) with the NINDS

of the NIH for a term of four years.

The Surgical Neurology Branch of NINDS is conducting research characterizing a variety of

compounds proprietary to the Company and is examining the potential of the compounds for anti-cancer activity, reducing neurological

deficit due to ischemia and brain injury, and stabilizing catalytic function of misfolded proteins for inborn brain diseases.

Under an M-CRADA, a party provides research material, in this case proprietary compounds from the Company’s pipeline, for

study by scientists at NIH.

The exchange of material was for research only and did not imply any endorsement of the material on

the part of either party.

Under the M-CRADA, the NIH grants a collaborator an exclusive option to elect an exclusive or non-exclusive

commercialization license.

June 14, 2017, the Company executed Amendment No.

1 to the M-CRADA, pursuant to which the Company agreed to provide funding in

the amount of $100,000 to the National Cancer Institute for use in acquiring technical, statistical and administrative support

for research activities.

The $100,000 amount was scheduled to be paid in two equal installments of $50,000, the first installment

of which was paid, as scheduled, on July 9, 2017, and was charged to research and development costs in the consolidated statement

of operations on such date.

The second installment of $50,000 was scheduled to be paid on the June 14, 2018 anniversary date of

the amendment and was accreted ratably through such date and included in research and development contract liabilities in the

Company’s consolidated balance sheet.

Pursuant to revised and updated collaboration plans, on November 3, 2018, the NINDS

and the Company agreed to a cancellation of the second installment payment of $50,000.

Accordingly, the previously accreted charge

of $50,000, of which $25,000 was recorded during the year ended December 31, 2018, was reversed during the during the year ended

December 31, 2018.

December 24, 2013, the Company entered into an agreement with NDA Consulting Corp.

(“NDA”) for consultation and advice

in the field of oncology research and drug development.

for consultation and advice in the field of

oncology research and drug development.

As part of the agreement, NDA also agreed to cause its president, Dr.

Von Hoff, M.D., to become a member of the Company’s Scientific Advisory Committee.

The term of the agreement was

for one year and provided for a quarterly cash fee of $4,000.

The agreement has been automatically renewed for additional one-year

terms on its anniversary date since 2014.

Consulting and advisory fees charged to operations pursuant to this agreement for the

years ended December 31, 2019 and 2018 were $16,000 and $16,000, respectively.

M.D., to become a member of the Company’s Scientific Advisory Committee.

The term of the agreement was for one year and

provided for a quarterly cash fee of $4,000.

The agreement has been automatically renewed for additional one-year terms on its

anniversary date since 2014.

Consulting and advisory fees charged to operations pursuant to this agreement were $16,000 and $62,000

for the years ended December 31, 2020 and 2019, respectively, which were included in research and development costs in the consolidated

statements of operations.

September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged

BioPharmaWorks to perform certain services for the Company.

Those services include, among other things:

Those services included, among other things:

(a) assisting the Company

14 unchanged sentences

hourly rate in lieu of the monthly payment and agreed to issue to BioPharmaWorks certain equity-based compensation.

2016, it was mutually agreed to suspend services and payments under the Collaboration Agreement, without extending its term, for

the period from November 1, 2016 through March 31, 2017.

The Collaboration Agreement resumed as scheduled on April 1, 2017.

April 2018, it was again mutually agreed to suspend services and payments under the Collaboration Agreement, without extending

its term, for the period from February 1, 2018 through the September 13, 2019 anniversary date.

In February 2019, the Company

and BioPharmaWorks subsequently agreed to resume the Collaboration Agreement effective March 1, 2019, and the Collaboration Agreement

is currently in effect.

The Company recorded charges to operations pursuant to this Collaboration Agreement for the years ended

December 31, 2019 and 2018 of $100,000 and $10,000, respectively, which were included in research and development costs in the

consolidated statement of operations.

In April 2018,

it was mutually agreed to suspend services and payments under the Collaboration Agreement, without extending its term, for the

period from February 1, 2018 through the September 13, 2019 anniversary date.

In February 2019, the Company and BioPharmaWorks

subsequently agreed to resume the Collaboration Agreement effective March 1, 2019, and the Collaboration Agreement is currently

The Company recorded charges to operations pursuant to this Collaboration Agreement of $131,650, including reimbursed

expenses of $11,650, and $100,000 for the years ended December 31, 2020 and 2019, respectively, which were included in research

and development costs in the consolidated statements of operations.

August 12, 2020, the Company entered into a Master Service Agreement with the Foundation for Angelman Syndrome Therapy (FAST)

to collaborate in supporting preclinical studies of the potential benefit of LB-100 in a mouse model of Angelman Syndrome (AS)

as reported in The Proceedings of The National Academy of Science (Wang et al, June 3, 2019).

The preclinical studies will take

place at The University of California - Davis under the direction of Dr.

David Segal, an internationally recognized leader in

If the preclinical studies confirm that LB-100 reduces AS signs in rodent models, the Company has agreed to enter

into discussions with FAST with respect to possible collaborations to most efficiently assess the benefit of LB-100 in patients

with AS, which is a rare disease affecting an estimated one out of 12,000 to one out of 20,000 persons in the United States.

genetic cause of AS, reduced function of a specific maternal gene called Ube3, has been understood for some time, but the molecular

abnormality resulting from the genetic lesion has now been shown to be increased concentrations of protein phosphatase 2A (PP2A),

a molecular target of the Company’s investigational compound, LB-100.

The Company has agreed to provide FAST with a supply

of LB-100 to be utilized in the conduct of this study, which is initially expected to be completed within three years.

on FAST’s completion of this study, the Company has agreed to pay FAST five percent (5%) of all proceeds, as defined in

the Master Service Agreement, received by the Company, up to a maximum of $250,000 from the exploitation of the study results.

December 21, 2020, the Company entered into a services agreement with IRTH Communications, LLC for investor/public relations,

financial communications and strategic consulting services, effective for an initial term of twelve months and renewable annually

The Company agreed to pay a monthly fee of $7,500, including any renewal term, and also agreed to issue restricted

shares of common stock, fully vested upon issuance, with a grant date fair value of $100,000.

Upon the commencement of any renewal

term, the Company will be obligated to issue additional restricted shares of common stock, fully vested upon issuance, with a

grant date fair value of $100,000.

Sheet Arrangements

1 unchanged sentence

sheet arrangements.

Events and Uncertainties

and development of new pharmaceutical compounds is, by its nature, unpredictable.

Although we will undertake research and development

efforts with commercially reasonable diligence, there can be no assurance that our cash position will be sufficient to enable

us to develop our pharmaceutical compounds to the extent needed to create future sales to sustain operations as contemplated herein.

can be no assurances that one or more of our pharmaceutical compounds will obtain the regulatory approvals and market acceptance

to achieve sustainable revenues sufficient to support our operations.

Even if we are able to generate revenues, there can be no

assurances that we will be able to achieve operating profitability or positive operating cash flows.

There can be no assurances

that we will be able to secure additional financing, to the extent required, on acceptable terms or at all.

If cash resources

are insufficient to satisfy our ongoing cash requirements, we would be required to reduce or discontinue our research and development

programs, or attempt to obtain funds, if available (although there can be no assurances), through strategic alliances that may

require us to relinquish rights to certain of our pharmaceutical compounds, or to curtail or discontinue our operations entirely.

than as discussed above, we are not currently aware of any trends, events or uncertainties that are likely to have a material

effect on our financial condition in the near term, although it is possible that new trends or events may develop in the future

that could have a material effect on our financial condition.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

Company’s consolidated financial statements and notes thereto and the related report of its independent registered public

accounting firm are attached to this Annual Report beginning on page F-1.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity